Activation of EGFR signaling, including EGFR gene amplification and occurrence of activation mutations, such as L858R and exon 19 deletions, is a major driving force for non-small-cell lung cancer (NSCLC), which accounts for approximately 85% of all lung cancer cases10,11. This evidence concerns the gene EGFR and lung cancer.